<![CDATA[Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors]]>
Although circulating tumor DNA (ctDNA) testing has emerged as powerful tools for detecting minimal residual disease (MRD) and refining risk stratification across solid tumors, questions remain about how best to integrate these assays into routine clinical …